These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34865146)

  • 1. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Nephrol Dial Transplant; 2022 May; 37(6):1171-1180. PubMed ID: 34865146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
    Kang ZY; Ma S; Liu W; Liu C
    Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin II type 1 receptor antibodies on graft function and survival in paediatric kidney transplant recipients.
    Kermond RF; Kim S; Mackie F; Hahn D; Carroll RP; Sharma A; Durkan AM
    HLA; 2024 Sep; 104(3):e15649. PubMed ID: 39247998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients.
    Sorohan BM; Ismail G; Berechet A; Obrișcă B; Constantinescu I; Mărunțelu I; Tacu D; Baston C; Sinescu I
    Transpl Immunol; 2021 Jun; 66():101389. PubMed ID: 33838295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Transpl Immunol; 2022 Jun; 72():101566. PubMed ID: 35257893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rejection and graft outcomes in kidney transplant recipients with and without angiotensin II receptor type 1 antibodies.
    Aljishi M; Isbel NM; Jegatheesan D; Johnson DW; Cho Y; Campbell SB; Hawley CM; Thornton A; Gillis D; Johnstone K
    Transpl Immunol; 2023 Feb; 76():101756. PubMed ID: 36460263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes.
    Zhang J; Wang M; Liang J; Zhang M; Liu XH; Ma L
    Int J Environ Res Public Health; 2017 May; 14(5):. PubMed ID: 28486415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
    Lee J; Huh KH; Park Y; Park BG; Yang J; Jeong JC; Lee J; Park JB; Cho JH; Lee S; Ro H; Han SY; Kim MS; Kim YS; Kim SJ; Kim CD; Chung W; Park SB; Ahn C;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1244-1250. PubMed ID: 26546592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
    Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
    Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
    Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
    Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria.
    Abuzeineh M; Aala A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 Jul; 21(1):253. PubMed ID: 32615995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.
    Pearl MH; Leuchter RK; Reed EF; Zhang Q; Ettenger RB; Tsai EW
    Pediatr Nephrol; 2015 Aug; 30(8):1371-4. PubMed ID: 25956702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.